Your browser doesn't support javascript.
loading
Chemotherapy in a Breast Cancer Patient Heterozygous Carrier of Ornithine Transcarbamylase Deficiency.
Palka-Kotlowska, Magda; Cabezón-Gutiérrez, Luis; Custodio-Cabello, Sara; Quijada-Fraile, PIlar; Chumillas-Calzada, Silvia.
Afiliação
  • Palka-Kotlowska M; Clinical Oncology, Hospital Universitario de Torrejón, Madrid, ESP.
  • Cabezón-Gutiérrez L; Medical Oncology, Hospital Universitario de Torrejón, Madrid, ESP.
  • Custodio-Cabello S; Medical Oncology, Hospital Universitario de Torrejón, Madrid, ESP.
  • Quijada-Fraile P; Unidad Pediátrica De Enfermedades Raras, Metabólicas-Hereditarias Y Mitocondriales, Hospital Universitario 12 de Octubre, Madrid, ESP.
  • Chumillas-Calzada S; Unidad Pediátrica De Enfermedades Raras, Metabólicas-Hereditarias Y Mitocondriales, Hospital Universitario 12 de Octubre, Madrid, ESP.
Cureus ; 12(5): e8301, 2020 May 26.
Article em En | MEDLINE | ID: mdl-32601573
ABSTRACT
Urea cycle disorders (UCDs) are an unusual genetic condition that may lead to hyperammonemia in catabolic situations such as surgery, infections or chemotherapy administration. Without specific treatment, it causes life-threatening encephalopathy. We present the case of a young woman, heterozygous carrier of ornithine transcarbamylase deficiency (OTCD) with breast cancer, who was treated with surgery, chemotherapy, radiotherapy and hormone therapy while following a protocol to minimize the risk of metabolic decompensation due to her condition.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline Idioma: En Ano de publicação: 2020 Tipo de documento: Article